Where the field is actually moving

Virtual visits in ocular oncology: The new era

Carol L. Shields, MD

“Imaging-only” surveillance for low-risk melanocytic lesions

Scott Walter, MD, MSc

A photoscreening pathway for choroidal nevus surveillance

Lauren A. Dalvin, MD

Impact of delayed referrals and the potential for improved outcomes with AI-assisted recommendations from fundus photos

Ezekiel Weis, MD, MPH

Panel Discussion

Previous session faculty and Zelia Maria Correa, MD, PhD

Integrated ophthalmic ultrasound: Enhancing usability and diagnostic utility

Michael J. Heiferman, MD

Ultrawide-field OCT in ocular oncology

Alison Skalet, MD, PhD, FACS

Polarization-diversity optical coherence tomography (PD-OCT) analysis and multimodal imaging of peripapillary melanocytomas

Zaid Mammo, MD, FRCSC

Panel Discussion

Previous session faculty and Zelia Maria Correa, MD, PhD

Uveal melanoma: What we know and what’s ahead

Carol L. Shields, MD

Targeted next-generation sequencing-based molecular profiling of ocular sebaceous carcinoma

Hakan Demirci, MD

Characterizing Elahere-associated ocular toxicities

Filippos Vingopoulos, MD, PhD

Beyond the challenge: Innovation in managing ocular surface neoplasia in Brazil

Priscilla Ballalai Bordon, MD

Panel Discussion

Session 2 faculty

Break and Exhibits

Aqueous humor liquid biopsy in uveal melanoma: A systematic review

Lauren Ong, BA

Meso-environment tissue culture model validation

Vinit B. Mahajan, MD, PhD

Circulating hybrid cells in uveal melanoma

Alison Skalet, MD, PhD, FACS

Reprogramming the immune response in uveal melanoma

J. William Harbour, MD

Panel Discussion

Session 3 faculty

The future of liquid biopsy

Ash A. Alizadeh, MD, PhD

Day 1 Concludes

Buses to Paul Brest West Hall

Reception

Presentation and Dinner

Buses return to hotel

In vitro and in vivo models for uveal melanoma

Lauren A. Dalvin, MD

Safety of needle biopsy of subfoveal and juxtapapillary choroidal lesions

Ezekiel Weis, MD, MPH

Development of a synthetic eye model for uveal melanoma biopsy training in ocular oncology

Maura Di Nicola, MD

Panel Discussion

Previous session faculty

NCCN: Its role in past and future care of uveal melanoma

Miguel A. Materin, MD

Uveal melanoma: Need for optimization of surveillance protocols

Arun Singh, MD

Panel Discussion

Previous session faculty

Updated indications of photodynamic therapy in ocular tumors

Brian Peter Marr, MD

Gamma knife and proton beam therapy: Indications, outcomes, controversies

Maria Pefkianaki, MD, MPH, PhD

Comparative outcomes of large uveal melanomas treated with brachytherapy using 75 versus 85 Gy

Zelia Maria Correa, MD, PhD

Panel Discussion

Previous session faculty

Efficacy and safety of anzutresgene autoleucel (anzu-cel, IMA203), a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a Ph 1 trial

Pauline Funchain, MD

Evidence based update on advanced disease

Sunil Arani Reddy, MD

What to do with all the tools: A strategic approach to patients with uveal melanoma

Marlana Orloff Dacey, MD

Darovasertib in primary uveal melanoma: Early evidence of tumor shrinkage, eye-sparing, and vision preservation

David A. Reichstein, MD

Immune related adverse reactions (irAE): Lessons from systemic side effects

Pauline Funchain, MD

Panel Discussion

Session 5 faculty and Dan S. Gombos, MD, FACS

Break and Exhibits

Sponsor Presentations

The potential unknown long term sequelae for IAC and Ivit injections in Rb

Dan S. Gombos, MD, FACS

Suprachoroidal delivery of chemotherapy in retinoblastoma: What is the preclinical evidence

Arun Singh, MD

LBSeq4Kids: Clinical implementation of an aqueous humor liquid biopsy platform for retinoblastoma and simulating lesions

Jesse Lee Berry, MD

Panel Discussion

Session 6 faculty

Lunch and Exhibits

The ALRN-6924 story

Matthew W. Wilson, MD, FACS

Updates on molecular diagnosis of vitreoretinal lymphoma

Maura Di Nicola, MD

Ocular toxicities of CAR-T therapy

Tara Murty

CAR-T therapy and lymphoma

David Miklos, MD, PhD

Panel Discussion

Session 7 faculty

New insights into the genetic evolution of uveal melanoma

J. William Harbour, MD

Multimodal deep learning for classification of uveal melanoma

Michael J. Heiferman, MD

Open source and bespoke models of uveal melanoma prognostication

Chase A. Ludwig, MD, MSc

Panel Discussion

All session faculty

Update on next-generation sequencing for uveal melanoma (long-term data)

Armin Afshar, MD, MBA

GPS-guided management of clinically indeterminate lesions: Biopsy first, then decide whether to treat or observe

Scott Walter, MD, MSc

Changes in GEP in observed indeterminate lesions

Ezekiel Weis, MD, MPH

Early detection of small, Class 2 choroidal melanomas using diagnostic FNAB

Zelia Maria Correa, MD, PhD

Panel Discussion

All session faculty

Break and Exhibits

Atypical choroidal melanoma

Vikas Khetan, MD

A very mysterious case

Brian Peter Marr, MD

Cyberknife stereotactic radiosurgery for nonresectable iris melanomas

Murat Tunc, MD

Beyond the vitreous

Purna Nangia

What lurks in the dark: A rare presentation of conjunctival melanoma in a young immunocompetent patient

Nida Safdar, MD

Retinoblastoma beyond initial remission: Highlighting the role of ongoing surveillance

Reem Alahmadi, MD

Bilateral panuveitis manifestation of myelodysplastic neoplasms associated autoinflammatory syndrome

Tina Tang, MD

Multiple melanomas in a single eye: BAP1, seeding, or just good luck?

Evandro Lucena, MD

Meeting Concludes